SDEE’s Investor Day with 5 AM Ventures

Apply for SDEE’s Investor Day with 5AM Ventures

Pitch Your Healthcare Startup and Network with Other CEOs/Founders

Submissions due by October 20th

Event Sponsor:

David Allison, PhD, Principal

Mira Chaurushiya, PhD, Senior Associate

5AM Ventures is a leading venture capital firm focused on building next-generation life science companies capable of delivering outstanding returns to our investors. We support companies that are working to solve important healthcare needs via cutting-edge breakthroughs in medicine and science. Our portfolio companies spearhead novel approaches to diagnose, prevent and treat a wide range of medical conditions.

5AM’s investment professionals possess strong scientific, medical, operational, legal and finance expertise. Our complementary backgrounds provide us with a unique edge to find and shape life science portfolio companies. Our team employs a time-tested, hands-on approach to company building and, in addition to being an early investor, 5AM is often directly involved in setting company strategy, management recruiting, business development and fundraising. We contribute as board members and frequently take on short-term operating roles.

To be considered for this event, please submit a one page executive summary, or a non-confidential slide deck (less than 25 slides) via email to: [email protected]

Participation in this event is subject to selection*, and only open to SDEE members. (Join here: http://www.sdentrepreneurs.org/join_sdee)

David Allison, Ph.D. joined 5AM Ventures as a Principal in 2016. He was previously a Principal at Versant Ventures, where he focused on biotechnology and other healthcare investments, and was involved with companies such as Aprea, BioTie Therapies (acquired by Acorda), Crinetics, Holaira and NeuWave Medical (acquired by Johnson and Johnson). Prior to Versant, Dr. Allison was a Principal at Split Rock Ventures where he was involved with companies such as Ardian (acquired by Medtronic), Histogenics (Nasdaq: HSGX), RF Surgical (acquired by Medtronic), Transcend (acquired by Alcon) and Twelve (acquired by Medtronic). Prior to Split Rock Ventures he was a Sr. Associate at PTV Sciences. David also spent time with SurModics in its diagnostics and drug discovery business unit and as a NSF Research Fellow at The Cleveland Clinic Foundation’s Heart Valve Laboratory. Dr. Allison received a Ph.D. in Bioengineering from Rice University with a focus in Cell Biology and Extracellular Matrix in Cardiovascular Disease. He received a B.S. in Biomedical Engineering from The University of Iowa. Dr. Allison is based in the San Francisco, CA office.

Mira Chaurushiya, Ph.D. is a Senior Associate at 5AM Ventures. Dr. Chaurushiya joined in 2015 from Genentech where she was a Postdoctoral Fellow in the Department of Physiological Chemistry studying mouse models of cancer and stem cells. Prior to Genentech, she completed her Ph.D. work at the Salk Institute, where she studied Herpes Simplex Virus infections and epigenetics. Her work has been published in Science and PNAS, among others. Dr. Chaurushiya currently serves as an Observer on the Boards of Chrono Therapeutics, Precision Nanosystems, Purigen Biosystems, Biodesy, Cleave Biosciences, GenePeeks and Pear Therapeutics. In addition, she is a Fellow of the Society of Kauffman Fellows and serves on the Board of Biotech Connection Bay Area, a non-profit that focuses on career development for academic scientists. Dr. Chaurushiya received a Ph.D. in Biological Sciences from the University of California, San Diego in conjunction with the Salk Institute for Biological Studies, where she was awarded the Martin Kamen Thesis Prize in Biochemistry. She received her B.A. in Biology from Carleton College. Dr. Chaurushiya is based in the San Francisco, CA office.

* You will be notified by October 31^st if your company is selected to participate.